PN
pornjarim nilyanimit
Research areas: Medicine · Infectious Diseases · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Cervical Cancer and HPV Research
0000-0003-2250-0017
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (11)
- Age-Specific Seroprevalence of Human Parvovirus B19 in Thailand: A Cross-Sectional Study Across Four Geographic Regions with Global Comparison Save
- Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model Save
- Hepatitis E in Thailand: From Seroprevalence to Foodborne and Transfusion-Associated Risks Save
- Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions Save
- Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection Save
- Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma Save
- SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis Save
- The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5 Save
- Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine Save
- Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination Save
- COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron Save